On March 9, 2020, Acorda Therapeutics, Inc. (NASDAQ:ACOR) announced that it has agreed to pay a $65 million penalty to settle charges brought by the U.S. Attorney's Office for the Southern District of New York.  The settlement is subject to court approval.  The SEC's complaint alleges that Acorda violated the antifraud provisions of Section 17(a) of the Securities Act of 1933 ("Securities Act") and Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act") and Rule 10b-5 thereunder.  Without admitting or denying the allegations in the SEC's complaint, Acorda has agreed to pay a penalty of $65 million, which is a 13.1% decrease over the first quarter of the year.  The settlement is subject to court approval, and the amount of the penalty will be determined by the court upon motion of the SEC.  The settlement is subject to court approval by the court.  The SEC's continuing investigation is being conducted by Boobalan Pachaiyappan with the assistance of the Laurenet Abuse Unit's Analysis and Detection Center.  The litigation will be led by Tierney Saccavino.  The SEC appreciates the assistance of the U.S. Attorney's Office for New York, the Federal Bureau of Investigation, and the Financial Industry Regulatory Authority.